Current concepts of mechanisms in drug-induced hepatotoxicity

Current Medicinal Chemistry

Volumn 16, Issue 23, 2009, Pages 3041-3053

  Russmann, Stefan ^a   Kullak Ublick, Gerd A ^a   Grattagliano, Ignazio ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Acetaminophen; Apoptosis; Death receptors; Drug metabolism; Drug induced liver injury; Fas; Glutathione; Hepatotoxicity; Metabonomics; Mitochondria; Mitochondrial permeability transition; Necrosis; TNF alpha

Indexed keywords

ACETYLSALICYLIC ACID; ACYLTRANSFERASE; AMIODARONE; BOSENTAN; CYTOCHROME P450; DICLOFENAC; GLUTATHIONE; STRESS ACTIVATED PROTEIN KINASE; TROGLITAZONE;

APOPTOSIS; CELL STRESS; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DRUG INDUCED DISEASE; ENVIRONMENTAL FACTOR; GENE ACTIVATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INNATE IMMUNITY; LIVER TOXICITY; MITOCHONDRIAL PERMEABILITY; NECROSIS; OXIDATIVE STRESS; PROTEIN DEPLETION; REVIEW; RISK ASSESSMENT; RISK FACTOR;

APOPTOSIS; HEPATITIS, TOXIC; HUMANS; MITOCHONDRIA, LIVER; NECROSIS; RISK FACTORS;

EID: 70349406480     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803097     Document Type: Review

References (126)

1. Ostapowicz, G.; Fontana, R.J.; Schiodt, F.V.; Larson, A.; Davern, T.J.; Han, S.H.; McCashland, T.M.; Shakil, A.O.; Hay, J.E.; Hynan, L.; Crippin, J.S.; Blei, A.T.; Samuel, G.; Reisch, J.; Lee, W.M. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med., 2002, 137(12), 947-954.
2. Lee, W.M. Acute liver failure in the United States. Semin. Liver Dis., 2003, 23(3), 217-226.
3. Biour, M.; Poupon, R.; Grange, J.D.; Chazouilleres, O. [Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs]. Gastroenterol. Clin. Biol., 2000, 24(11), 1052-1091.
4. Chitturi, S.; Farrell, G.C. Hepatotoxic slimming aids and other herbal hepatotoxins. J. Gastroenterol. Hepatol., 2008, 23(3), 366-373.
5. Seeff, L.B. Herbal hepatotoxicity. Clin. Liver Dis., 2007, 11(3), 577-596.
6. Schoepfer, A.M.; Engel, A.; Fattinger, K.; Marbet, U.A.; Criblez, D.; Reichen, J.; Zimmermann, A.; Oneta, C.M. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J. Hepatol., 2007, 47(4), 521-526.
7. Temple, R.J.; Himmel, M.H. Safety of newly approved drugs: Implications for prescribing. JAMA, 2002, 287(17), 2273-2275.
8. Kaplowitz, N. Drug-induced liver disorders: Implications for drug development and regulation. Drug Saf., 2001, 24(7), 483-490.
9. Krahenbuhl, S.; Brauchli, Y.; Kummer, O.; Bodmer, M.; Trendelenburg, M.; Drewe, J.; Haschke, M. Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage. Digestion, 2007, 75(4), 232-237.
10. Thummel, K.E.; Slattery, J.T.; Ro, H.; Chien, J.Y.; Nelson, S.D.; Lown, K.E.; Watkins, P.B. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin. Pharmacol. Ther., 2000, 67(6), 591-599.
11. Shayiq, R.M.; Roberts, D.W.; Rothstein, K.; Snawder, J.E.; Benson, W.; Ma, X.; Black, M. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: An explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology, 1999, 29(2), 451-463.
12. Seguin, B.; Uetrecht, J. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol., 2003, 3(4), 235-242.
13. Kalgutkar, A.S.; Gardner, I.; Obach, R.S.; Shaffer, C.L.; Callegari, E.; Henne, K.R.; Mutlib, A.E.; Dalvie, D.K.; Lee, J.S.; Nakai, Y.; O'Donnell, J.P.; Boer, J.; Harriman, S.P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 2005, 6(3), 161-225.
14. Touloukian, J.; Kaplowitz, N. Halothane-induced hepatic disease. Semin. Liver Dis., 1981, 1(2), 134-142.
15. Boelsterli, U.A. Mechanisms of NSAID-induced hepatotoxicity: Focus on nimesulide. Drug Saf., 2002, 25(9), 633-648.
16. Spahn-Langguth, H.; Benet, L.Z. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev., 1992, 24(1), 5-47.
17. Pauli-Magnus, C.; Stieger, B.; Meier, Y.; Kullak-Ublick, G.A.; Meier, P.J. Enterohepatic transport of bile salts and genetics of cholestasis. J. Hepatol., 2005, 43(2), 342-357.
18. Vendemiale, G.; Grattagliano, I.; Altomare, E.; Turturro, N.; Guerrieri, F. Effect of acetaminophen administration on hepatic glutathione compartmentation and mitochondrial energy metabolism in the rat. Biochem. Pharmacol., 1996, 52(8), 1147-1154.
19. Kaufmann, P.; Torok, M.; Hanni, A.; Roberts, P.; Gasser, R.; Krahenbuhl, S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology, 2005, 41(4), 925-935.
20. Pessayre, D.; Mansouri, A.; Haouzi, D.; Fromenty, B. Hepatotoxicity due to mitochondrial dysfunction. Cell. Biol. Toxicol., 1999, 15(6), 367-373.
21. Waldhauser, K.M.; Torok, M.; Ha, H.R.; Thomet, U.; Konrad, D.; Brecht, K.; Follath, F.; Krahenbuhl, S. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther., 2006, 319(3), 1413-1423.
22. Candelli, M.; Miele, L.; Armuzzi, A.; Nista, E.C.; Pignataro, G.; Fini, L.; Cazzato, I.A.; Zocco, M.A.; Bartolozzi, F.; Gasbarrini, G.; Grieco, A.; Gasbarrini, A. 13C-methionine breath tests for mitochondrial liver function assessment. Eur. Rev. Med. Pharmacol. Sci., 2008, 12(4), 245-249.
23. 13C]methionine. Hepatology, 2002, 36(5), 1190-1196.
24. Spahr, L.; Negro, F.; Rubbia-Brandt, L.; Marinescu, O.; Goodman, K.; Jordan, M.; Frossard, J.L.; Hadengue, A. Acute valproate-associated microvesicular steatosis: Could the [13C]methionine breath test be useful to assess liver mitochondrial function? Dig. Dis. Sci., 2001, 46(12), 2758-2761.
25. Njoku, D. B.; Greenberg, R.S.; Bourdi, M.; Borkowf, C.B.; Dake, E.M.; Martin, J.L.; Pohl, L.R. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth. Analg., 2002, 94(2), 243-249.
26. Robin, M.A.; Le Roy, M.; Descatoire, V.; Pessayre, D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J. Hepatol., 1997, 26 Suppl 1, 23-30.
27. Lakehal, F.; Dansette, P.M.; Becquemont, L.; Lasnier, E.; Delelo, R.; Balladur, P.; Poupon, R.; Beaune, P.H.; Housset, C. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem. Res. Toxicol., 2001, 14(6), 694-701.
28. Jaskiewicz, K.; Voigt, H.; Blakolmer, K. Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J. Toxicol. Clin. Toxicol., 1996, 34(3), 301-305.
29. DeLeve, L.D.; Shulman, H.M.; McDonald, G.B. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis., 2002, 22(1), 27-42.
30. Malhi, H.; Gores, G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology, 2008, 134(6), 1641-1654.
31. Gunawan, B.K.; Liu, Z.X.; Han, D.; Hanawa, N.; Gaarde, W.A.; Kaplowitz, N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology, 2006, 131(1), 165-178.
32. Henderson, N.C.; Pollock, K.J.; Frew, J.; Mackinnon, A.C.; Flavell, R.A.; Davis, R.J.; Sethi, T.; Simpson, K.J. Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure. Gut, 2007, 56(7), 982-990.
33. Latchoumycandane, C.; Goh, C.W.; Ong, M.M.; Boelsterli, U.A. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology, 2007, 45(2), 412-421.
34. Schwabe, R.F.; Brenner, D.A. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: Role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290(4), G583-589.
35. Scaffidi, C.; Schmitz, I.; Zha, J.; Korsmeyer, S.J.; Krammer, P.H.; Peter, M.E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem., 1999, 274(32), 22532-22538.
36. Lemasters, J.J.; Qian, T.; Bradham, C.A.; Brenner, D.A.; Cascio, W.E.; Trost, L.C.; Nishimura, Y.; Nieminen, A.L.; Herman, B. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J. Bioenerg. Biomembr., 1999, 31(4), 305-319.
37. Haouzi, D.; Lekehal, M.; Moreau, A.; Moulis, C.; Feldmann, G.; Robin, M.A.; Letteron, P.; Fau, D.; Pessayre, D. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology, 2000, 32(2), 303-311.
38. Pessayre, D.; Haouzi, D.; Fau, D.; Robin, M.A.; Mansouri, A.; Berson, A. Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: Different forms of drug-induced hepatic apoptosis. J. Hepatol., 1999, 31(4), 760-770.
39. Feldmann, G.; Haouzi, D.; Moreau, A.; Durand-Schneider, A.M.; Bringuier, A.; Berson, A.; Mansouri, A.; Fau, D.; Pessayre, D. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology, 2000, 31(3), 674-683.
40. Slee, E.A.; Adrain, C.; Martin, S.J. Executioner caspase-3, -6, and - 7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem., 2001, 276(10), 7320-7326.
41. Formigli, L.; Papucci, L.; Tani, A.; Schiavone, N.; Tempestini, A.; Orlandini, G.E.; Capaccioli, S.; Orlandini, S.Z. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J. Cell. Physiol., 2000, 182(1), 41-49.
42. Papucci, L.; Formigli, L.; Schiavone, N.; Tani, A.; Donnini, M.; Lapucci, A.; Perna, F.; Tempestini, A.; Witort, E.; Morganti, M.; Nosi, D.; Orlandini, G.E.; Zecchi Orlandini, S.; Capaccioli, S. Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expression. Cell Tissue Res., 2004, 316(2), 197-209.
43. Leist, M.; Single, B.; Castoldi, A.F.; Kuhnle, S.; Nicotera, P. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J. Exp. Med., 1997, 185(8), 1481-1486.
44. Papa, S.; Zazzeroni, F.; Bubici, C.; Jayawardena, S.; Alvarez, K.; Matsuda, S.; Nguyen, D.U.; Pham, C.G.; Nelsbach, A.H.; Melis, T.; De Smaele, E.; Tang, W.J.; D'Adamio, L.; Franzoso, G. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat. Cell Biol., 2004, 6(2), 146-153.
45. Wang, X.; Tomso, D.J.; Chorley, B.N.; Cho, H.Y.; Cheung, V.G.; Kleeberger, S.R.; Bell, D.A. Identification of polymorphic antioxidant response elements in the human genome. Hum. Mol. Genet., 2007, 16(10), 1188-1200.
46. Ginn-Pease, M.E.; Whisler, R.L. Optimal NF kappa B mediated transcriptional responses in Jurkat T cells exposed to oxidative stress are dependent on intracellular glutathione and costimulatory signals. Biochem. Biophys. Res. Commun., 1996, 226(3), 695-702.
47. Mihm, S.; Galter, D.; Droge, W. Modulation of transcription factor NF kappa B activity by intracellular glutathione levels and by variations of the extracellular cysteine supply. FASEB J., 1995, 9(2), 246-252.
48. Cazanave, S.; Berson, A.; Haouzi, D.; Vadrot, N.; Fau, D.; Grodet, A.; Letteron, P.; Feldmann, G.; El-Benna, J.; Fromenty, B.; Robin, M.A.; Pessayre, D. High hepatic glutathione stores alleviate Fas-induced apoptosis in mice. J. Hepatol., 2007, 46(5), 858-868.
49. Swain, M.G. Hepatic NKT cells: Friend or foe? Clin. Sci. (Lond.), 2008, 114(7), 457-466.
50. Cazanave, S.; Vadrot, N.; Tinel, M.; Berson, A.; Letteron, P.; Larosche, I.; Descatoire, V.; Feldmann, G.; Robin, M.A.; Pessayre, D. Ibuprofen administration attenuates serum TNF-alpha levels, hepatic glutathione depletion, hepatic apoptosis and mouse mortality after Fas stimulation. Toxicol. Appl. Pharmacol., 2008, 231(3), 336-343.
51. Michalopoulos, G.K. Liver regeneration. J. Cell. Physiol., 2007, 213(2), 286-300.
52. Mehendale, H.M. Tissue repair: An important determinant of final outcome of toxicant-induced injury. Toxicol. Pathol., 2005, 33(1), 41-51.
53. Wang, T.; Shankar, K.; Ronis, M.J.; Mehendale, H.M. Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit. Rev. Toxicol., 2007, 37(5), 413-459.
54. Anand, S.S.; Murthy, S.N.; Vaidya, V.S.; Mumtaz, M.M.; Mehendale, H.M. Tissue repair plays pivotal role in final outcome of liver injury following chloroform and ally1 alcohol binary mixture. Food Chem. Toxicol., 2003, 41(8), 1123-1132.
55. Apte, U.M.; Limaye, P.B.; Ramaiah, S.K.; Vaidya, V.S.; Bucci, T.J.; Warbritton, A.; Mehendale, H.M. Upregulated promitogenic signaling via cytokines and growth factors: Potential mechanism of robust liver tissue repair in calorie-restricted rats upon toxic challenge. Toxicol. Sci., 2002, 69(2), 448-459.
56. Limaye, P.B.; Bhave, V.S.; Palkar, P.S.; Apte, U.M.; Sawant, S.P.; Yu, S.; Latendresse, J.R.; Reddy, J.K.; Mehendale, H.M. Upregulation of calpastatin in regenerating and developing rat liver: Role in resistance against hepatotoxicity. Hepatology, 2006, 44(2), 379-388.
57. Grattagliano, I.; Lauterburg, B.H.; Portincasa, P.; Caruso, M.L.; Vendemiale, G.; Valentini, A.M.; Palmieri, V.O.; Palasciano, G. Mitochondrial glutathione content determines the rate of liver regeneration after partial hepatectomy in eu- and hypothyroid rats. J. Hepatol., 2003, 39(4), 571-579.
58. Vendemiale, G.; Guerrieri, F.; Grattagliano, I.; Didonna, D.; Muolo, L.; Altomare, E. Mitochondrial oxidative phosphorylation and intracellular glutathione compartmentation during rat liver regeneration. Hepatology, 1995, 21(5), 1450-1454.
59. Andrade, R.J.; Lucena, M.I.; Kaplowitz, N.; Garcia-Munoz, B.; Borraz, Y.; Pachkoria, K.; Garcia-Cortes, M.; Fernandez, M.C.; Pelaez, G.; Rodrigo, L.; Duran, J.A.; Costa, J.; Planas, R.; Barrio-canal, A.; Guarner, C.; Romero-Gomez, M.; Munoz-Yague, T.; Salmeron, J.; Hidalgo, R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44(6), 1581-1588.
60. Russmann, S.; Iselin, H.U.; Meier, D.; Zimmermann, A.; Simon, H.U.; Caduff, P.; Reichen, J. Acute hepatitis associated with montelukast. J. Hepatol., 2003, 38(5), 694-695.
61. Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov., 2005, 4(6), 489-499.
62. Copple, I.M.; Goldring, C.E.; Jenkins, R.E.; Chia, A.J.; Randle, L.E.; Hayes, J.D.; Kitteringham, N.R.; Park, B.K. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology, 2008, 48(4), 1292-1301.
63. Copple, I.M.; Goldring, C.E.; Kitteringham, N.R.; Park, B.K. The Nrf2-Keap1 defence pathway: Role in protection against drug-induced toxicity. Toxicology, 2008, 246(1), 24-33.
64. Goldring, C.E.; Kitteringham, N.R.; Elsby, R.; Randle, L.E.; Clement, Y.N.; Williams, D.P.; McMahon, M.; Hayes, J.D.; Itoh, K.; Yamamoto, M.; Park, B.K. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology, 2004, 39(5), 1267-1276.
65. Russmann, S.; Lauterburg, B.H.; Helbling, A. Kava hepatotoxicity. Ann. Intern. Med., 2001, 135(1), 68-69.
66. Stickel, F.; Baumuller, H.M.; Seitz, K.; Vasilakis, D.; Seitz, G.; Seitz, H.K.; Schuppan, D. Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol., 2003, 39(1), 62-67.
67. Russmann, S.; Barguil, Y.; Cabalion, P.; Kritsanida, M.; Duhet, D.; Lauterburg, B.H. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol., 2003, 15(9), 1033-1036.
68. Lude, S.; Torok, M.; Dieterle, S.; Jaggi, R.; Buter, K.B.; Krahenbuhl, S. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine, 2008, 15(1-2), 120-131.
69. Zenger, F.; Russmann, S.; Junker, E.; Wuthrich, C.; Bui, M.H.; Lauterburg, B.H. Decreased glutathione in patients with anorexia nervosa. Risk factor for toxic liver injury? Eur. J. Clin. Nutr., 2004, 58(2), 238-243.
70. Lauterburg, B.H.; Velez, M.E. Glutathione deficiency in alcoholics: Risk factor for paracetamol hepatotoxicity. Gut, 1988, 29(9), 1153-1157.
71. Zhang, J.; Huang, W.; Chua, S.S.; Wei, P.; Moore, D.D. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science, 2002, 298(5592), 422-424.
72. Chan, K.; Han, X.D.; Kan, Y.W. An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA, 2001, 98(8), 4611-4616.
73. Enomoto, A.; Itoh, K.; Nagayoshi, E.; Haruta, J.; Kimura, T.; O'Connor, T.; Harada, T.; Yamamoto, M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci., 2001, 59(1), 169-177.
74. Ishida, Y.; Kondo, T.; Ohshima, T.; Fujiwara, H.; Iwakura, Y.; Mukaida, N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J., 2002, 16(10), 1227-1236.
75. Ishida, Y.; Kondo, T.; Tsuneyama, K.; Lu, P.; Takayasu, T.; Mukaida, N. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J. Leukoc. Biol., 2004, 75(1), 59-67.
76. Liu, Z.X.; Kaplowitz, N. Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol., 2006, 2(4), 493-503.
77. Laskin, D.L.; Gardner, C.R.; Price, V.F.; Jollow, D.J. Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology, 1995, 21(4), 1045-1050.
78. Liu, Z.X.; Han, D.; Gunawan, B.; Kaplowitz, N. Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology, 2006, 43(6), 1220-1230.
79. Nagai, H.; Matsumaru, K.; Feng, G.; Kaplowitz, N. Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology, 2002, 36(1), 55-64.
80. Matsumaru, K.; Ji, C.; Kaplowitz, N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology, 2003, 37(6), 1425-1434.
81. Mansouri, A.; Demeilliers, C.; Amsellem, S.; Pessayre, D.; Fromenty, B. Acute ethanol administration oxidatively damages and depletes mitochondrial dna in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J. Pharmacol. Exp. Ther., 2001, 298(2), 737-743.
82. Barnes, S.N.; Aleksunes, L.M.; Augustine, L.; Scheffer, G.L.; Goedken, M.J.; Jakowski, A.B.; Pruimboom-Brees, I.M.; Cherrington, N.J.; Manautou, J.E. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab. Dispos., 2007, 35(10), 1963-1969.
83. Agundez, J.A.; Ladero, J.M. Glutathione S-transferase GSTT1 and GSTM1 allozymes: Beyond null alleles. Pharmacogenomics, 2008, 9(3), 359-363.
84. Huang, Y.S.; Su, W.J.; Huang, Y.H.; Chen, C.Y.; Chang, F.Y.; Lin, H.C.; Lee, S.D. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:qUinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol., 2007, 47(1), 128-134.
85. Huang, Y.S.; Chern, H.D.; Su, W.J.; Wu, J.C.; Chang, S.C.; Chiang, C.H.; Chang, F.Y.; Lee, S.D. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 2003, 37(4), 924-930.
86. Huang, Y.S.; Chern, H.D.; Su, W.J.; Wu, J.C.; Lai, S.L.; Yang, S.Y.; Chang, F.Y.; Lee, S.D. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology, 2002, 35(4), 883-889.
87. Lee, Y.H.; Boelsterli, U.A.; Lin, Q.; Chung, M.C. Proteomics profiling of hepatic mitochondria in heterozygous Sod2+/- mice, an animal model of discreet mitochondrial oxidative stress. Proteomics, 2008, 8(3), 555-568.
88. Rieder, M.J.; Shear, N.H.; Kanee, A.; Tang, B.K.; Spielberg, S.P. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin. Pharmacol. Ther., 1991, 49(1), 13-17.
89. Simon, T.; Becquemont, L.; Mary-Krause, M.; de Waziers, I.; Beaune, P.; Funck-Brentano, C.; Jaillon, P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther., 2000, 67(4), 432-437.
90. Njoku, D.; Laster, M.J.; Gong, D.H.; Eger, E.I., 2nd; Reed, G.F.; Martin, J.L. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury. Anesth. Analg., 1997, 84(1), 173-178.
91. Andrade, R.J.; Lucena, M.I.; Alonso, A.; Garcia-Cortes, M.; Garcia-Ruiz, E.; Benitez, R.; Fernandez, M.C.; Pelaez, G.; Romero, M.; Corpas, R.; Duran, J.A.; Jimenez, M.; Rodrigo, L.; Nogueras, F.; Martin-Vivaldi, R.; Navarro, J.M.; Salmeron, J.; de la Cuesta, F.S.; Hidalgo, R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39(6), 1603-1612.
92. Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A.M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F.T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359(9308), 727-732.
93. Mallal, S.; Phillips, E.; Carosi, G.; Molina, J.M.; Workman, C.; Tomazic, J.; Jagel-Guedes, E.; Rugina, S.; Kozyrev, O.; Cid, J.F.; Hay, P.; Nolan, D.; Hughes, S.; Hughes, A.; Ryan, S.; Fitch, N.; Thorborn, D.; Benbow, A. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med., 2008, 358(6), 568-579.
94. Aithal, G.P.; Ramsay, L.; Daly, A.K.; Sonchit, N.; Leathart, J.B.; Alexander, G.; Kenna, J.G.; Caldwell, J.; Day, C.P. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology, 2004, 39(5), 1430-1440.
95. Ibdah, J.A.; Bennett, M.J.; Rinaldo, P.; Zhao, Y.; Gibson, B.; Sims, H.F.; Strauss, A.W. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N. Engl. J. Med., 1999, 340(22), 1723-1731.
96. Strauss, A.W.; Bennett, M.J.; Rinaldo, P.; Sims, H.F.; O'Brien, L.K.; Zhao, Y.; Gibson, B.; Ibdah, J. Inherited long-chain 3- hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin. Perinatol., 1999, 23(2), 100-112.
97. Pessayre, D.; Berson, A.; Fromenty, B.; Mansouri, A. Mitochondria in steatohepatitis. Semin. Liver Dis., 2001, 21(1), 57-69.
98. Sohal, R.S.; Weindruch, R. Oxidative stress, caloric restriction, and aging. Science, 1996, 273(5271), 59-63.
99. Boelsterli, U.A.; Lim, P.L. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol., 2007, 220(1), 92-107.
100. Nardo, B.; Caraceni, P.; Pasini, P.; Domenicali, M.; Catena, F.; Cavallari, G.; Santoni, B.; Maiolini, E.; Grattagliano, I.; Vendemiale, G.; Trevisani, F.; Roda, A.; Bernardi, M.; Cavallari, A. Increased generation of reactive oxygen species in isolated rat fatty liver during postischemic reoxygenation. Transplantation, 2001, 71(12), 1816-1820.
101. Vendemiale, G.; Grattagliano, I.; Caraceni, P.; Caraccio, G.; Domenicali, M.; Dall'Agata, M.; Trevisani, F.; Guerrieri, F.; Bernardi, M.; Altomare, E. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status. Hepatology, 2001, 33(4), 808-815.
102. Donthamsetty, S.; Bhave, V.S.; Mitra, M.S.; Latendresse, J.R.; Mehendale, H.M. Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity. Hepatology, 2007, 45(2), 391-403.
103. Meier, C.R.; Krahenbuhl, S.; Schlienger, R.G.; Jick, H. Association between body mass index and liver disorders: An epidemiological study. J. Hepatol., 2002, 37(6), 741-747.
104. Bohan, A.; Boyer, J.L. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin. Liver Dis., 2002, 22(2), 123-136.
105. Eloranta, J.J.; Kullak-Ublick, G.A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys., 2005, 433(2), 397-412.
106. Fattinger, K.; Funk, C.; Pantze, M.; Weber, C.; Reichen, J.; Stieger, B.; Meier, P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther., 2001, 69(4), 223-231.
107. Lang, C.; Meier, Y.; Stieger, B.; Beuers, U.; Lang, T.; Kerb, R.; Kullak-Ublick, G.A.; Meier, P.J.; Pauli-Magnus, C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics, 2007, 17(1), 47-60.
108. Stieger, B.; Fattinger, K.; Madon, J.; Kullak-Ublick, G.A.; Meier, P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, 2000, 118(2), 422-430.
109. Funk, C.; Ponelle, C.; Scheuermann, G.; Pantze, M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol., 2001, 59(3), 627-635.
110. Meier, Y.; Zodan, T.; Lang, C.; Zimmermann, R.; Kullak-Ublick, G.A.; Meier, P.J.; Stieger, B.; Pauli-Magnus, C. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J. Gastroenterol., 2008, 14(1), 38-45.
111. Dixon, P.H.; van Mil, S.; Chambers, J.; Strautnieks, S.; Thompson, R.; Lammert, F.; Kubitz, R.; Keitel, V.; Glantz, A.; Mattsson, L.A.; Marschall, H.U.; Molokhia, M.; Moore, G.; Linton, K.; Williamson, C. Contribution of Variant Alleles of ABCB11 to Susceptibility to Intrahepatic Cholestasis of Pregnancy. Gut, 2008, 58(4), 537-44.
112. Liddle, C.; Goodwin, B. Regulation of hepatic drug metabolism: Role of the nuclear receptors PXR and CAR. Semin. Liver Dis., 2002, 22(2), 115-122.
113. Deng, X.; Stachlewitz, R.F.; Liguori, M.J.; Blomme, E.A.; Waring, J.F.; Luyendyk, J.P.; Maddox, J.F.; Ganey, P.E.; Roth, R.A. Modest inflammation enhances diclofenac hepatotoxicity in rats: Role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther., 2006, 319(3), 1191-1199.
114. Deschamps, D.; Fisch, C.; Fromenty, B.; Berson, A.; Degott, C.; Pessayre, D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J. Pharmacol. Exp. Ther., 1991, 259(2), 894-904.
115. Lauterburg, B.H.; Grattagliano, I.; Gmur, R.; Stalder, M.; Hildebrand, P. Noninvasive assessment of the effect of xenobiotics on mitochondrial function in human beings: Studies with acetylsalicylic acid and ethanol with the use of the carbon 13-labeled ketoisocaproate breath test. J. Lab. Clin. Med., 1995, 125(3), 378-383.
116. Bruno, R.; Sacchi, P.; Maiocchi, L.; Patruno, S.; Filice, G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review. Dig. Liver Dis., 2006, 38(6), 363-373.
117. Sulkowski, M.S. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver Dis., 2003, 23(2), 183-194.
118. Botla, R.; Spivey, J.R.; Aguilar, H.; Bronk, S.F.; Gores, G.J. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: A mechanism of UDCA cytoprotection. J. Pharmacol. Exp. Ther., 1995, 272(2), 930-938.
119. Rodrigues, C.M.; Fan, G.; Ma, X.; Kren, B.T.; Steer, C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest., 1998, 101(12), 2790-2799.
120. Bjornsson, E. Drug-induced liver injury: Hy's rule revisited. Clin. Pharmacol. Ther., 2006, 79(6), 521-528.
121. Kaplowitz, N. Rules and laws of drug hepatotoxicity. Pharmacoepidemiol. Drug Saf., 2006, 15(4), 231-233.
122. Hoofnagle, J.H. Drug-induced liver injury network (DILIN). Hepatology, 2004, 40(4), 773.
123. Watkins, P.B.; Seeff, L.B. Drug-induced liver injury: Summary of a single topic clinical research conference. Hepatology, 2006, 43(3), 618-631.
124. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statininduced myopathy - a genomewide study. N. Engl. J. Med., 2008, 359(8), 789-799.
125. Grassi, A.; Susca, M.; Ferri, S.; Gabusi, E.; D'Errico, A.; Farina, G.; Maccariello, S.; Zauli, D.; Bianchi, F.B.; Ballardini, G. Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: Timing and patterns of positivity on frozen and paraffinembedded sections. Am. J. Clin. Pathol., 2004, 121(2), 211-219.
126. Wieckowska, A.; Zein, N.N.; Yerian, L.M.; Lopez, A.R.; McCullough, A.J.; Feldstein, A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology, 2006, 44(1), 27-33.